Iswarya Fertility Center has secured a primary investment of $37 million from OrbiMed Asia VI Mauritius Limited, an investment vehicle of OrbiMed.
Trilegal advised Iswarya Health Private Limited (the parent company of Iswarya Fetility Center), and its promoters, Dr. Arun Muthuvel, Dr. S. Chandralekha and Dr. K. Veluswamy, on this transaction.
The transaction was led by Rahul Chugh (Partner), with support from Kriti Chatrath (Senior Associate) and Samridhi Poddar (Associate).
CMS INDUSLAW advised OrbiMed on this transaction.
The CMS INDUSLAW team comprised of the following:
Kartik Ganapathy (Founding and Senior Partner) provided strategic inputs on certain aspects of the transaction.
Aakash Dasgupta (Partner), Ravin Abhyankar (Senior Associate), Anshul Bhuwalka (Senior Associate) and Saumya Joshi (Associate), advised on the transaction.
Shantanu Jindel (Partner) advised on the regulatory aspects of the transaction.
Associates Aanshavi Srishti, Abhinav A, Suryanshu Mishra and Samarth Jain assisted with Due Diligence.
Ruhi Jain (Executive Director), Praveen Hegde (Manager) and Adarsh Joshi (Assistant Manager) advised on Corporate Secretarial aspects of the transaction.
Bharadwaj Jaishankar (Partner) and Trushita Mehra (Senior Associate) advised on Intellectual Property aspects.
Founded in 1987, Iswarya Fertility Center has grown into a nationwide fertility network with 87+ centres across India and has helped over 300,000 couples through advanced fertility treatments and reproductive healthcare services.
The investment marks Iswarya's first institutional capital raise and will support its next phase of expansion, including strengthening its clinical capabilities, expanding its footprint and enhancing access to fertility care across India.
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.